

Supplementary Table. CSF detectability of the molecules examined in CIS and RR-MS patients, separated in three groups, according to DMTs (IFN-beta, glatiramer acetate, dimethyl fumarate)

CSF molecules	IFN-beta (n=116)	Glatiramer acetate (n=51)	Dimethyl fumarate (n=59)
IL-1 β	52.9 %	60.7 %	57.4 %
IL-1ra	53.3 %	87.5 %	87.2 %
IL-2	51.9 %	46.7 %	50.0 %
IL-4	56.9 %	72.3 %	73.2 %
IL-5	55.6 %	74.4 %	70.0 %
IL-6	97.4 %	89.8 %	75.0 %
IL-7	82.6 %	76.1 %	60.4 %
IL-8	100 %	100 %	100 %
IL-9	97.3 %	90.6 %	91.5 %
IL-10	71.1 %	93.9 %	94.6 %
IL-12	78.0 %	76.1 %	60.0 %
IL-13	95.3 %	97.7 %	100 %
IL-15	61.3 %	40.6 %	31.9 %
IL-17	40.6 %	55.0 %	61.7 %
TNF α	73.6 %	82.6 %	88.9 %
IFN γ	68.9 %	66.7 %	85.7 %
MIP-1 α	43.6 %	96.6 %	100 %
MIP-1 β	93.9 %	97.9 %	100 %
MCP-1	100 %	100 %	100 %
IP-10	89.3 %	96.8 %	100 %
Eotaxin	65.3 %	83.9 %	93.6 %
GM-CSF	59.6 %	53.2 %	39.3 %
G-CSF	97.4 %	97.9 %	98.2 %
PDGF	56.0 %	38.7 %	38.3 %
FGF	28.0 %	45.2 %	51.1 %
VEGF	69.4 %	70.0 %	58.3 %
RANTES	69.3 %	77.4 %	80.9 %

Abbreviations:

CIS, clinically isolated syndrome; CSF, cerebrospinal fluid; DMT, disease modifying therapy; FGF, fibroblast growth factor; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; MCP, monocyte chemoattractant protein; IP-10, interferon gamma-induced protein 10; MIP, macrophage inflammatory protein; PDGF, platelet-derived growth factor; ra, receptor antagonist;

RANTES, Regulated on Activation Normal T Cell Expressed and Secreted; RR-MS, relapsing-remitting multiple sclerosis; TNF, tumor necrosis factor; VEGF, vascular-endothelial growth factor;